Home > Insider Trading > Filing (0000899243-17-003618)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252524	Von Kurt Emster	C/O Crispr Therapeutics, Inc. 200 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2016-10-24	2,354,050	$0.00	2,354,050	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2016-10-24	191,764	$0.00	2,545,814	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2016-10-24	56,000	$14.00	2,601,814	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Series A-3 Preferred Shares	Disposition	2016-10-24	2,354,050	$0.00	2,354,050	$0.00
Common Shares	Series B Preferred Shares	Disposition	2016-10-24	191,764	$0.00	191,764	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.
These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.